Testing equivalence of two doses of intravenous iron to treat iron deficiency in pregnancy: A randomised controlled trial
Date
2023
Authors
Froessler, B.
Schubert, K.O.
Palm, P.
Church, R.
Aboustate, N.
Kelly, T.
Dekker, G.A.
Hodyl, N.A.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
BJOG: An International Journal of Obstetrics and Gynaecology, 2023; 130(1):15-23
Statement of Responsibility
Conference Name
Abstract
Objective: To test the equivalence of two doses of intravenous iron (ferric carboxymaltose) in pregnancy.
Design: Parallel, two-arm equivalence randomised controlled trial with an equivalence margin of 5%.
Setting: Single centre in Australia.
Population: 278 pregnant women with iron deficiency.
Methods: Participants received either 500 mg (n = 152) or 1000 mg (n = 126) of intravenous ferric carboxymaltose in the second or third trimester.
Main outcome measures: The proportion of participants requiring additional intravenous iron (500 mg) to achieve and maintain ferritin >30 microg/L (diagnostic threshold for iron deficiency) at 4 weeks post-infusion, and at 6 weeks, and 3-, 6- and 12-months postpartum. Secondary endpoints included repeat infusion rate, iron status, birth and safety outcomes.
Results: The two doses were not equivalent within a 5% margin at any time point. At 4 weeks post infusion, 26/73 (36%) participants required a repeat infusion in the 500-mg group compared with 5/67 (8%) in the 1000-mg group: difference in proportions, 0.283 (95% confidence interval [CI] 0.177–0.389). Overall, participants in the 500-mg arm received twice the repeat infusion rate (0.81 [SD = 0.824] versus 0.40 [SD = 0.69], rate ratio 2.05, 95% CI 1.45–2.91).
Conclusions: Administration of 1000 mg ferric carboxymaltose in pregnancy maintains iron stores and reduces the need for repeat infusions. A 500- mg dose requires ongoing monitoring to ensure adequate iron stores are reached and sustained.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2022 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made (https://creativecommons.org/licenses/by-nc-nd/4.0/)